These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 23552470

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
    Wakelee HA, Takimoto CH, Lopez-Anaya A, Chu Q, Middleton G, Dunlop D, Ramlau R, Leighl N, Rowinsky EK, Hao D, Zatloukal P, Jacobs CD, Rodon J.
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):563-71. PubMed ID: 22057855
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
    Motonaga M, Yamamoto N, Makino Y, Ando-Makihara R, Ohe Y, Takano M, Hayashi Y.
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):713-21. PubMed ID: 26233803
    [Abstract] [Full Text] [Related]

  • 7. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH.
    J Clin Oncol; 2004 Mar 01; 22(5):785-94. PubMed ID: 14990633
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bexarotene and erlotinib for aerodigestive tract cancer.
    Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, Dmitrovsky E.
    J Clin Oncol; 2005 Dec 01; 23(34):8757-64. PubMed ID: 16314636
    [Abstract] [Full Text] [Related]

  • 10. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
    Milton DT, Riely GJ, Azzoli CG, Gomez JE, Heelan RT, Kris MG, Krug LM, Pao W, Pizzo B, Rizvi NA, Miller VA.
    Cancer; 2007 Aug 01; 110(3):599-605. PubMed ID: 17577220
    [Abstract] [Full Text] [Related]

  • 11. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
    Wolf M, Swaisland H, Averbuch S.
    Clin Cancer Res; 2004 Jul 15; 10(14):4607-13. PubMed ID: 15269131
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors.
    Fakih MG, Trump DL, Muindi JR, Black JD, Bernardi RJ, Creaven PJ, Schwartz J, Brattain MG, Hutson A, French R, Johnson CS.
    Clin Cancer Res; 2007 Feb 15; 13(4):1216-23. PubMed ID: 17317832
    [Abstract] [Full Text] [Related]

  • 14. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.
    Laurie SA, Gauthier I, Arnold A, Shepherd FA, Ellis PM, Chen E, Goss G, Powers J, Walsh W, Tu D, Robertson J, Puchalski TA, Seymour L.
    J Clin Oncol; 2008 Apr 10; 26(11):1871-8. PubMed ID: 18398152
    [Abstract] [Full Text] [Related]

  • 15. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
    Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K, SIGN Study Group.
    Anticancer Drugs; 2006 Apr 10; 17(4):401-9. PubMed ID: 16549997
    [Abstract] [Full Text] [Related]

  • 16. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
    Blumenschein GR, Khuri FR, von Pawel J, Gatzemeier U, Miller WH, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A.
    J Clin Oncol; 2008 Apr 10; 26(11):1879-85. PubMed ID: 18398153
    [Abstract] [Full Text] [Related]

  • 17. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
    Rigas JR, Dragnev KH.
    Oncologist; 2005 Jan 10; 10(1):22-33. PubMed ID: 15632250
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.